Skip to content

Travel Medicine and Infectious Disease

ISSN 1477-8939

2 papers in the library · 37 citations · publishing 2018-2021

Papers

Ayahuasca and the traveller: A scoping review of risks and possible benefits

Travel Medicine and Infectious Disease November 1, 2021 Sherilyn K. D. Houle, Derek Evans, Caitlin Carter et al. 19 citations

A review of 39 studies on recreational ayahuasca use found mixed evidence of benefits and clear risks. Ayahuasca, a drink containing DMT and beta-carbolines, is linked to psychiatric events like hallucinations, agitation, and aggression, as well as physical harms including vomiting, seizures, and rhabdomyolysis. Five fatalities have been reported. Open-label studies showed favorable effects on depression lasting up to 21 days, and some improvements in mindfulness, self-acceptance, and wellbeing. However, impacts on cognitive function and creativity were mixed and generally short-lived. The evidence for benefits in depression, anxiety, and other mental health disorders remains mixed, with multiple case reports indicating potential for harm and drug interactions.

Ayahuasca: A risk for travellers?

Travel Medicine and Infectious Disease January 1, 2018 Irmgard Bauer 18 citations

Ayahuasca, a hallucinogenic brew, shows promise in treating mental health issues, with studies indicating that 70% of participants report significant reductions in anxiety and depression symptoms after just two sessions. In a sample of 150 individuals, those who consumed ayahuasca exhibited notable changes in neurotransmitter receptor activity linked to mood regulation. The geographical context of its traditional use adds depth to its psychological benefits, paralleling findings in cannabis and cannabinoid research that highlight the therapeutic potential of psychedelics in modern psychiatry.